Valine.

Valine, leucine and isoleucine share one transaminase and one branched-chain ketoacid dehydrogenase complex, so they are handled as a set. Leucine drives the muscle protein synthesis signal while valine supplies the balance of the branched-chain pool it draws on.

The first step of valine metabolism is transamination by branched-chain aminotransferase, an enzyme that works only with pyridoxal 5-phosphate bound. B6 status therefore sets how readily valine enters its own catabolic route.

The branched-chain ketoacid dehydrogenase complex that clears the ketoacid formed from valine uses thiamine pyrophosphate at its E1 subunit. Thiamine availability is what keeps that decarboxylation step moving.

Valine and tryptophan cross the blood brain barrier on the same large neutral amino acid carrier, so a large valine dose lowers tryptophan uptake into the brain. Separate them in time when the tryptophan is the point of the serving.

Valine and leucine share one aminotransferase and one ketoacid dehydrogenase complex. Leucine alone speeds that complex and pulls valine down with it, so blends keep them balanced.

The branched-chain ketoacid dehydrogenase complex and the acyl-CoA dehydrogenase downstream both carry FAD. Riboflavin keeps those flavins loaded.

NAD is the terminal electron acceptor for the dehydrogenase complex handling valine's ketoacid. Niacin maintains that pool.

Valine carbon travels as isobutyryl-CoA and later acyl-CoA forms, all built on coenzyme A. Pantothenic acid is the precursor of that carrier.

Propionyl-CoA from valine breakdown is carboxylated by a biotin-dependent enzyme. Biotin gates that step toward the citric acid cycle.

Methylmalonyl-CoA formed from valine is rearranged into succinyl-CoA by a B12-dependent mutase. Without B12 that step cannot finish.

Nitrogen removed from valine in muscle is passed to glutamate and leaves mostly as glutamine. The two sit at either end of that handoff.

Branched-chain nitrogen also leaves muscle as alanine through the glucose-alanine cycle. Alanine is the carrier for that nitrogen.

Tyrosine uses the same large neutral amino acid carrier valine occupies. A large branched-chain dose lowers tyrosine entry into the brain.

5-HTP crosses on the large neutral amino acid carrier valine also uses. Taken together, valine reduces how much 5-HTP gets across.

Norvaline is the straight-chain form of valine and competes for the same transport. The pairing is competitive rather than additive.

The branched chain ketoacid dehydrogenase complex that oxidises valine's transamination product carries a lipoamide arm on its E2 subunit, so lipoic acid is a structural cofactor of the step. Endogenous synthesis normally covers this, and supplemental lipoic acid is not the same thing as a rate limiting supply. The relationship is textbook enzymology rather than a supplementation finding.

Valine and isoleucine are transaminated by the same branched chain aminotransferase and oxidised by the same dehydrogenase complex, and both feed carbon into succinyl coenzyme A. Supplying one alone shifts the ratio at that shared enzyme, which is why branched chain products keep all three together. Valine and isoleucine also compete for the same intestinal and blood brain transporters.

Valine and phenylalanine are both large neutral amino acids carried by the LAT1 transporter at the gut and the blood brain barrier. A large valine dose lowers phenylalanine entry into brain tissue and the same is true in the other direction. This is transport arithmetic, not an effect of either amino acid on the other's metabolism.

Methionine shares the LAT1 carrier with valine, so the two compete for the same uptake capacity when taken in the same dose. At ordinary dietary amounts the competition is unremarkable; at bolus supplement amounts it shifts the plasma ratio measurably. Spacing large free amino acid doses is the usual response.

Histidine is carried in part by the same large neutral amino acid system that moves valine, so a concentrated free form dose of one reduces uptake of the other. The interaction matters most for free amino acid products taken away from food. Whole protein delivers the same amino acids at ratios that do not produce this effect.

Whey is naturally rich in branched chain amino acids and already supplies valine alongside leucine and isoleucine at a fixed ratio. Adding free valine on top of an adequate whey intake mostly changes that ratio rather than the total. Products that stack the two are supplying the same amino acid twice.

Casein supplies valine as part of a slowly digested protein, giving a lower and longer plasma amino acid curve than free valine does. The two differ in kinetics rather than in the amino acid delivered. Pairing them is a way to cover both the fast and the slow part of that curve.

Creatine works on phosphocreatine resynthesis while valine contributes to muscle protein substrate supply, so the two act on separate steps rather than the same one. Co-formulation is common in training products for that reason. There is no combination trial that isolates valine's contribution to the pairing.

Carnitine accepts acyl groups from coenzyme A, which relieves acyl coenzyme A build up in the mitochondrion, and branched chain amino acid catabolism generates exactly those acyl intermediates. Isobutyryl carnitine is the recognised marker of valine flux through that route. The relationship is a metabolic buffering one, described in metabolite terms rather than as a supplementation outcome.

Glycine conjugates excess acyl groups from branched chain amino acid breakdown, and acylglycines are the urinary markers used to track that pathway. Adequate glycine supports the normal disposal route for those intermediates. This describes a metabolic hand off rather than an effect on valine's usefulness.

The kinase that switches the branched chain ketoacid dehydrogenase complex off is an ATP dependent enzyme, and ATP acts as a magnesium complex in every such reaction. Magnesium is therefore part of the regulatory machinery over valine oxidation. It is a background cofactor requirement, not a dose response relationship with valine.